Investors purchased shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) on weakness during trading on Thursday. $35.83 million flowed into the stock on the tick-up and $19.15 million flowed out of the stock on the tick-down, for a money net flow of $16.68 million into the stock. Of all stocks tracked, Zimmer Biomet had the 27th highest net in-flow for the day. Zimmer Biomet traded down ($1.00) for the day and closed at $114.78
A number of equities research analysts have weighed in on the stock. TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a report on Friday, November 24th. Zacks Investment Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research report on Tuesday, November 14th. Edward Jones upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. Finally, Royal Bank Of Canada dropped their price target on shares of Zimmer Biomet to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 7th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $133.71.
The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $23,383.62, a PE ratio of 14.31, a PEG ratio of 1.79 and a beta of 1.15.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same quarter in the previous year, the firm earned $1.79 EPS. The firm’s revenue was down .8% on a year-over-year basis. analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Ingalls & Snyder LLC lifted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after acquiring an additional 507 shares during the period. Koch Industries Inc. increased its stake in Zimmer Biomet by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after purchasing an additional 1,038,674 shares in the last quarter. Jensen Investment Management Inc. increased its stake in Zimmer Biomet by 24.2% during the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 1,140 shares in the last quarter. Andra AP fonden increased its stake in Zimmer Biomet by 15.8% during the 2nd quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock valued at $2,735,000 after purchasing an additional 2,900 shares in the last quarter. Finally, Commerce Bank increased its stake in Zimmer Biomet by 1.5% during the 2nd quarter. Commerce Bank now owns 218,171 shares of the medical equipment provider’s stock valued at $28,013,000 after purchasing an additional 3,142 shares in the last quarter. Institutional investors own 86.24% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Traders Buy Shares of Zimmer Biomet (ZBH) on Weakness” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/07/traders-buy-shares-of-zimmer-biomet-zbh-on-weakness.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.